{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:55:37Z","timestamp":1794578137370,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"39","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41388-018-0340-y","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T10:08:05Z","timestamp":1527761285000},"page":"5292-5304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide"],"prefix":"10.1038","volume":"37","author":[{"given":"Lu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saijun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-5434","authenticated-orcid":false,"given":"Qiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"340_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"340_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","volume":"7","author":"RW Carlson","year":"2009","unstructured":"Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7:122\u201392.","journal-title":"J Natl Compr Cancer Netw"},{"key":"340_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med"},{"key":"340_CR4","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","volume":"9 Suppl 2","author":"CK Anders","year":"2009","unstructured":"Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9 Suppl 2:S73\u201381.","journal-title":"Clin Breast Cancer"},{"key":"340_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.7150\/jca.4925","volume":"4","author":"G Tinoco","year":"2013","unstructured":"Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117\u201332.","journal-title":"J Cancer"},{"key":"340_CR6","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.2010.32.1877","volume":"29","author":"LF Hernandez-Aya","year":"2011","unstructured":"Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2628\u201334.","journal-title":"J Clin Oncol"},{"key":"340_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/107327481001700306","volume":"17","author":"K Turaga","year":"2010","unstructured":"Turaga K, Acs G, Laronga C. Gene expression profiling in breast cancer. Cancer Control. 2010;17:177\u201382.","journal-title":"Cancer Control"},{"key":"340_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrc1650","volume":"5","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5:516\u201325.","journal-title":"Nat Rev Cancer"},{"key":"340_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell Jr","year":"1997","unstructured":"Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630\u20135.","journal-title":"Science"},{"key":"340_CR10","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474\u201388.","journal-title":"Oncogene"},{"key":"340_CR11","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ijc.29923","volume":"138","author":"K Banerjee","year":"2016","unstructured":"Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138:2570\u20138.","journal-title":"Int J Cancer"},{"key":"340_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1074-7613(00)80005-9","volume":"10","author":"K Takeda","year":"1999","unstructured":"Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10:39\u201349.","journal-title":"Immunity"},{"key":"340_CR13","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.4049\/jimmunol.161.9.4652","volume":"161","author":"K Takeda","year":"1998","unstructured":"Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol. 1998;161:4652\u201360.","journal-title":"J Immunol"},{"key":"340_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","volume":"415","author":"Y Wang","year":"2018","unstructured":"Wang Y, Shen Y, Wang S, Shen Q, Zhou X. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett. 2018;415:117\u201328.","journal-title":"Cancer Lett"},{"key":"340_CR15","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.18632\/oncotarget.6855","volume":"7","author":"JS Kim","year":"2016","unstructured":"Kim JS, Kim HA, Seong MK, Seol H, Oh JS, Kim EK, et al. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. Oncotarget. 2016;7:7055\u201365.","journal-title":"Oncotarget"},{"key":"340_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0099-5428(05)32002-8","volume":"32","author":"BM Al-Hadiya","year":"2005","unstructured":"Al-Hadiya BM. Niclosamide: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2005;32:67\u201396.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"340_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1021\/ml100146z","volume":"1","author":"X Ren","year":"2010","unstructured":"Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett. 2010;1:454\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"340_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/1535-7163.MCT-13-0555","volume":"13","author":"AI Londono-Joshi","year":"2014","unstructured":"Londono-Joshi AI, Arend RC, Aristizabal L, Lu W, Samant RS, Metge BJ, et al. Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther. 2014;13:800\u201311.","journal-title":"Mol Cancer Ther"},{"key":"340_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085887","volume":"9","author":"T Ye","year":"2014","unstructured":"Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu L, et al. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS ONE. 2014;9:e85887.","journal-title":"PLoS ONE"},{"key":"340_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074538","volume":"8","author":"YC Wang","year":"2013","unstructured":"Wang YC, Chao TK, Chang CC, Yo YT, Yu MH, Lai HC. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS ONE. 2013;8:e74538.","journal-title":"PLoS ONE"},{"key":"340_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","volume":"12","author":"T Gritsko","year":"2006","unstructured":"Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11\u201319.","journal-title":"Clin Cancer Res"},{"key":"340_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/1535-7163.MCT-13-0608","volume":"13","author":"S You","year":"2014","unstructured":"You S, Li R, Park D, Xie M, Sica GL, Cao Y, et al. Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther. 2014;13:606\u201316.","journal-title":"Mol Cancer Ther"},{"key":"340_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1172\/JCI0215617","volume":"109","author":"J Bromberg","year":"2002","unstructured":"Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109:1139\u201342.","journal-title":"J Clin Invest"},{"key":"340_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature07733","volume":"458","author":"M Diehn","year":"2009","unstructured":"Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780\u20133.","journal-title":"Nature"},{"key":"340_CR25","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1038\/onc.2010.238","volume":"29","author":"T Shimura","year":"2010","unstructured":"Shimura T, Kakuda S, Ochiai Y, Nakagawa H, Kuwahara Y, Takai Y, et al. Acquired radioresistance of human tumor cells by DNA-PK\/AKT\/GSK3beta-mediated cyclin D1 overexpression. Oncogene. 2010;29:4826\u201337.","journal-title":"Oncogene"},{"key":"340_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bbamcr.2017.10.006","volume":"1865","author":"S Desai","year":"2018","unstructured":"Desai S, Barai A, Bukhari AB, De A, Sen S. alpha-Actinin-4 confers radioresistance coupled invasiveness in breast cancer cells through AKT pathway. Biochim Biophys Acta. 2018;1865:196\u2013208.","journal-title":"Biochim Biophys Acta"},{"key":"340_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.yexcr.2017.11.037","volume":"362","author":"Y Jin","year":"2018","unstructured":"Jin Y, Xu K, Chen Q, Wang B, Pan J, Huang S, et al. Simvastatin inhibits the development of radioresistant esophageal cancer cells by increasing the radiosensitivity and reversing EMT process via the PTEN-PI3K\/AKT pathway. Exp Cell Res. 2018;362:362\u20139.","journal-title":"Exp Cell Res"},{"key":"340_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.radonc.2014.07.015","volume":"112","author":"T Shimura","year":"2014","unstructured":"Shimura T, Noma N, Sano Y, Ochiai Y, Oikawa T, Fukumoto M, et al. AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells. Radiother Oncol. 2014;112:302\u20137.","journal-title":"Radiother Oncol"},{"key":"340_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/OTT.S76958","volume":"8","author":"H Liu","year":"2015","unstructured":"Liu H, Yang W, Gao H, Jiang T, Gu B, Dong Q, et al. Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair. Onco Targets Ther. 2015;8:509\u201318.","journal-title":"Onco Targets Ther"},{"key":"340_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/jcb.24465","volume":"114","author":"EJ Kim","year":"2013","unstructured":"Kim EJ, Jeong JH, Bae S, Kang S, Kim CH, Lim YB. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy. J Cell Biochem. 2013;114:1248\u201356.","journal-title":"J Cell Biochem"},{"key":"340_CR31","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/cas.13323","volume":"108","author":"K Sato","year":"2017","unstructured":"Sato K, Azuma R, Imai T, Shimokawa T. Enhancement of mTOR signaling contributes to acquired X-ray and C-ion resistance in mouse squamous carcinoma cell line. Cancer Sci. 2017;108:2004\u201310.","journal-title":"Cancer Sci"},{"key":"340_CR32","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2174\/156800912803251243","volume":"12","author":"FJ Dumont","year":"2012","unstructured":"Dumont FJ, Bischoff P. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. Curr Cancer Drug Targets. 2012;12:899\u2013924.","journal-title":"Curr Cancer Drug Targets"},{"key":"340_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/1078-0432.CCR-17-0345","volume":"24","author":"X Wang","year":"2017","unstructured":"Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca K, et al. Honokiol radiosensitizes squamous cell carcinoma of the head and neck by downregulation of survivin. Clin Cancer Res. 2017;24:858\u201369.","journal-title":"Clin Cancer Res"},{"key":"340_CR34","doi-asserted-by":"publisher","first-page":"C1640","DOI":"10.1152\/ajpcell.1998.275.6.C1640","volume":"275","author":"AR Simon","year":"1998","unstructured":"Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol. 1998;275:C1640\u20131652.","journal-title":"Am J Physiol"},{"key":"340_CR35","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1074\/jbc.M307251200","volume":"279","author":"T Liu","year":"2004","unstructured":"Liu T, Castro S, Brasier AR, Jamaluddin M, Garofalo RP, Casola A. Reactive oxygen species mediate virus-induced STAT activation: role of tyrosine phosphatases. J Biol Chem. 2004;279:2461\u20139.","journal-title":"J Biol Chem"},{"key":"340_CR36","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.bcp.2012.02.010","volume":"83","author":"X Liu","year":"2012","unstructured":"Liu X, Guo W, Wu S, Wang L, Wang J, Dai B, et al. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012;83:1456\u201364.","journal-title":"Biochem Pharmacol"},{"key":"340_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.biopha.2017.09.149","volume":"96","author":"X Li","year":"2017","unstructured":"Li X, Ding R, Han Z, Ma Z, Wang Y. Targeting of cell cycle and let-7a\/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. Biomed Pharmacother. 2017;96:434\u201342.","journal-title":"Biomed Pharmacother"},{"key":"340_CR38","doi-asserted-by":"publisher","first-page":"86803","DOI":"10.18632\/oncotarget.13466","volume":"7","author":"RC Arend","year":"2016","unstructured":"Arend RC, Londono-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, et al. Niclosamide and its analogs are potent inhibitors of Wnt\/beta-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget. 2016;7:86803\u201315.","journal-title":"Oncotarget"},{"key":"340_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jinorgbio.2017.08.020","volume":"176","author":"I Marmol","year":"2017","unstructured":"Marmol I, Virumbrales-Munoz M, Quero J, Sanchez-de-Diego C, Fernandez L, Ochoa I, et al. Alkynyl gold(I) complex triggers necroptosis via ROS generation in colorectal carcinoma cells. J Inorg Biochem. 2017;176:123\u201333.","journal-title":"J Inorg Biochem"},{"key":"340_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14329","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Su SS, Zhao S, Yang Z, Zhong CQ, Chen X, et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome. Nat Commun. 2017;8:14329.","journal-title":"Nat Commun"},{"key":"340_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5732\/cjc.011.10290","volume":"31","author":"JX Pan","year":"2012","unstructured":"Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31:178\u201384.","journal-title":"Chin J Cancer"},{"key":"340_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","volume":"41","author":"W Chen","year":"2018","unstructured":"Chen W, Mook RA Jr., Premont RT, Wang J. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018;41:89\u201396.","journal-title":"Cell Signal"},{"key":"340_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11060-016-2231-9","volume":"130","author":"TJ Han","year":"2016","unstructured":"Han TJ, Cho BJ, Choi EJ, Kim DH, Song SH, Paek SH, et al. Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. J Neurooncol. 2016;130:89\u201398.","journal-title":"J Neurooncol"},{"key":"340_CR44","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","volume":"70","author":"Y Jin","year":"2010","unstructured":"Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010;70:2516\u201327.","journal-title":"Cancer Res"},{"key":"340_CR45","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1158\/1541-7786.MCR-08-0238","volume":"7","author":"SR Walker","year":"2009","unstructured":"Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009;7:966\u201376.","journal-title":"Mol Cancer Res"},{"key":"340_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ni.1995","volume":"12","author":"XP Yang","year":"2011","unstructured":"Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011;12:247\u201354.","journal-title":"Nat Immunol"},{"key":"340_CR47","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/leu.2017.338","volume":"32","author":"B Peter","year":"2018","unstructured":"Peter B,Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018;32:1016\u20131022.","journal-title":"Leukemia"},{"key":"340_CR48","volume":"2","author":"JE Yeh","year":"2013","unstructured":"Yeh JE, Toniolo PA, Frank DA. JAK2-STAT5 signaling: a novel mechanism of resistance to targeted PI3K\/mTOR inhibition. JAKSTAT. 2013;2:e24635.","journal-title":"JAKSTAT"},{"key":"340_CR49","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011;117:3409\u201320.","journal-title":"Blood"},{"key":"340_CR50","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1158\/1078-0432.CCR-05-0562","volume":"11","author":"H Li","year":"2005","unstructured":"Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 2005;11:5863\u20138.","journal-title":"Clin Cancer Res"},{"key":"340_CR51","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1158\/0008-5472.CAN-04-4614","volume":"65","author":"T Wang","year":"2005","unstructured":"Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 2005;65:10338\u201346.","journal-title":"Cancer Res"},{"issue":"9 Supplement","key":"340_CR52","doi-asserted-by":"publisher","first-page":"P6-12-04-P6-12-","DOI":"10.1158\/1538-7445.SABCS14-P6-12-04","volume":"75","author":"Lili Wang","year":"2015","unstructured":"Wang L, Yang Z, Xia Q, Chen H, Cai G, Wild C, Zhou J, Shen Q. Targeting STAT3 with novel small molecule inhibitors to sensitize breast cancer cells to radiation therapy. Cancer Res. 2015;75. In: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX. https:\/\/doi.org\/10.1158\/1538-7445.SABCS14-P6-12-04 . Abstract P6-12-04.","journal-title":"Cancer Research"},{"key":"340_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.freeradbiomed.2016.09.007","volume":"99","author":"L Lu","year":"2016","unstructured":"Lu L, Dong J, Li D, Zhang J, Fan S. 3,3\u2019-diindolylmethane mitigates total body irradiation-induced hematopoietic injury in mice. Free Radic Biol Med. 2016;99:463\u201371.","journal-title":"Free Radic Biol Med"},{"key":"340_CR54","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/1535-7163.MCT-16-0606","volume":"16","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wang S, Wu Y, Ren Y, Li Z, Yao X, et al. Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21\/beta-catenin axis with HJC0152. Mol Cancer Ther. 2017;16:578\u201390.","journal-title":"Mol Cancer Ther"},{"key":"340_CR55","doi-asserted-by":"publisher","first-page":"18650","DOI":"10.1073\/pnas.1308206110","volume":"110","author":"S Fan","year":"2013","unstructured":"Fan S, Meng Q, Xu J, Jiao Y, Zhao L, Zhang X, et al. DIM (3,3\u2019-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci USA. 2013;110:18650\u20135.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0340-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T22:32:45Z","timestamp":1693693965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":55,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0340-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}